The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Evening all
What a wonderful buying opportunity at this level, my average is £1.89 and I’m still positive!
I’m definitely not selling, why would I? Everything points to a positive outcome...imho
Personally I sleep very well, but if I didn’t I would sell, everyone needs to be confident in their investments...
Good luck everyone :)
Boyg same, de-ramper
90p is here again!
Let’s hope results offset this decline
Dumb, your posts tell everyone what they need to know, check history and bore off. Sorry if you lost out. Wouldn't wish that on anyone.
I'm going to continue to build my holding here and just wait for the "take over" or "buy out" RNS as it will arrive IMO - Lets not forget the 15 years COPD research and development that SNG have in the bank!.
What can be bad about being able to average down further? The lower your average the more money you'll make when the share price takes off...
Tlw, agree with and I'll add that there has been no tr1 issued which, given the volume the other Friday was a pleasant surprise, suggesting it is pi's who have been selling rather than the possibly more well informed IIs.
Feeling quite relaxed waiting on news from P3 and activ2. The games with the share price were to be expected and don’t affect my view on this companies future. Happy to be patient
"the management have dragged their feet and now the sp is a quid"
I have read the opposite view in several sources. Although the time line in completing the SNG001 Phase III trials and, perhaps, moving on to emergency acceptance where the product is most needed appears to be slow from an investor's standpoint, the company is actually navigating its way through a complex process at a pace which is deemed as rapid by industry experts.
In my view, the share price decline is linked to the perceived long time scale - by quick profit seekers, who have sold their stock and moved elsewhere to seek faster gains in their investment.
I believe that patient long-term shareholders will be the ultimate beneficiaries once the significant phase III results, and perhaps other meaningful data emerge. Regards.
Using your own exact words whilst others panicking on the ARB BB recently...…...
'Relax, you are in too deep if this is getting to you.'
Using your own exact words whilst others panicking on the ARB BB recently...…...
'Relax, you are in too deep if this is getting to you.'
Come off it the management have dragged their feet and now the sp is a quid. It's absolutely terrible from them.
30 April 2021 RNS :
The degree of breathlessness at start of treatment indicates which patients should be treated with SNG001 both in hospital and at home
- Analysis of the combined data from the Hospital and Home Cohorts showed that the more breathless patients are significantly more likely (>3 fold) to recover on inhaled interferon beta (SNG001) than placebo
- The study results reinforce confidence in ongoing Phase III study, with data readout on track for H2 2021
Richard Marsden, CEO of Synairgen, said: "I am delighted by the finding that SNG001 treatment led to a threefold likelihood of recovery to 'no limitation of activities' in the markedly/severely breathless population compared to those on placebo in the home and hospital setting, and that further analyses reinforce our previous findings. It increases our conviction in the approach we have taken to conduct an international Phase III trial in hospitalised patients requiring supplemental oxygen, which is scheduled to read out in the second half of this year.
Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton, commented: "The SG016 COVID-19 trial of inhaled interferon beta has been very successful. Although the vast majority of non-hospitalised patients had very mild symptoms, the effects of SNG001 on the small group of markedly and severely breathless patients indicated who might be benefitting most from SNG001. Assessment of breathlessness as a predictor of protracted recovery in the combined Home and Hospital Cohorts showed us that non-breathless patients have no need for the innate immune response boost that interferon beta provides, whereas the patients who were breathless derive strong benefit from SNG001. This tells us that we should target SNG001 at COVID-19 patients with marked or severe breathlessness where it has a potentially significant benefit."
My assessment : The Activ-2 may need tweaking based on above output to target more directly the most 'at need' patients
Global Phase 3 bang on track and will produce stunning results. Then we will see all the big Pharma boys biting Synairgen's hand off. Also suspect that this 30% share decline over past few weeks is a result of nervous PI's, whilst the large institutional investment companies will be quietly building their portfolio's (most under the radar thresholds)
Patience will serve all LTHolders well :-)